An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)

• Status: Completed
• Trial end date: 2005-10-15
• Target enrollment: 0
• Participant gender: All

Summary

This trial was a randomized trial to determine a patient's acceptability of unflavored antipsychotic medication compared to raspberry flavored antipsychotic medication. Patients received 6 total doses of study drug (2 doses of each asenapine formulation) over 3 consecutive days: 2 different formulations each day, 1 in the morning and 1 in the evening. The formulations were: white unflavored, white raspberry flavored, and red raspberry flavored. Patients were given a questionnaire following each dose of study medication (one questionnaire twice per day for 3 days) to measure how acceptable each formulation was.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Asenapine

Criteria

Inclusion Criteria:

• are at least 18 years of age and of legal minimum age for trial participation;

• are a male, or a female who is not of childbearing potential

• are free from an acute exacerbation of psychosis for at least 3 months;

• have a current DSM-IV diagnosis of schizophrenia (paranoid, disorganized, catatonic, or undifferentiated subtype), or schizoaffective disorder; delusional disorder, major depressive disorder, or bipolar disorder, for whom chronic antipsychotic therapy is indicated;

• correctly identify 3 out of 4 basic flavors (bitter, sweet, salty, or sour) on a neutral taste paradigm;

• are receiving oral antipsychotic medication.

Exclusion Criteria:

• an uncontrolled, unstable clinically significant medical condition

• clinically significant abnormal laboratory, vital sign, PE, or ECGs findings at Screening;

• previously experienced NMRB (also known as vasovagal reflex) or sensitivity for fainting;

• a positive serum pregnancy test at screening, or the intention to become pregnant within the next 30 days;

• a history of seizures;

• a history of neuromalignant syndrome;

• a current (past 6 months) substance abuse or dependence according to DSM-IV-TR criteria (excluding nicotine);

• an imminent risk of self-harm or harm to others;

• currently receiving a depot antipsychotic, such as fluphenazine decanoate, haloperidol decanoate, or Risperdal Consta, within at least 1 dosing cycle of Day-5;

• any impairment in taste functioning;

• receiving lithium or topiramate;

• judged by the principal investigator (PI) to be unable to reliably respond to the questionnaire based on clinically significant cognitive impairment.